Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 78,844 shares of the biopharmaceutical company’s stock after purchasing an additional 5,045 shares during the period. First Citizens Bank & Trust Co.’s holdings in Gilead Sciences were worth $11,752,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of GILD. Davidson Trust Co. raised its stake in shares of Gilead Sciences by 4.1% in the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 74 shares during the period. Grove Bank & Trust grew its stake in shares of Gilead Sciences by 1.2% during the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock worth $946,000 after acquiring an additional 74 shares during the period. Financial Connections Group Inc. grew its stake in shares of Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 76 shares during the period. Wilkerson Advisory Group LLC grew its stake in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares during the period. Finally, Balboa Wealth Partners increased its holdings in Gilead Sciences by 2.7% in the 1st quarter. Balboa Wealth Partners now owns 3,057 shares of the biopharmaceutical company’s stock worth $426,000 after acquiring an additional 79 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the completion of the transaction, the chief executive officer owned 566,683 shares of the company’s stock, valued at approximately $83,812,415.70. This trade represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares of the company’s stock, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock valued at $14,940,540 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $147.92 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $183.41 billion, a P/E ratio of -55.40 and a beta of 0.31. The business has a fifty day simple moving average of $145.77 and a two-hundred day simple moving average of $136.87. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.01 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Thursday, October 8th. Finally, Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $123.00 to $126.00 and gave the company a “sector perform” rating in a research note on Thursday, October 8th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $159.33.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain bullish on Gilead, highlighting the company among attractive healthcare stocks. The positive view reflects Gilead’s HIV, liver-disease and oncology franchises, as well as its longer-term growth prospects. Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD)
• Positive Sentiment: Bank of America said survey results support a favorable long-term outlook for Yeztugo, Gilead’s HIV-prevention drug. Strong adoption potential could provide an additional growth driver for the company’s HIV portfolio. Gilead Sciences’ Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
• Positive Sentiment: Erste Group Bank modestly raised its FY2027 EPS forecast for Gilead to $9.90 from $9.88, signaling confidence in the company’s future profitability. Erste Group Bank Raises Gilead Sciences EPS Estimate
• Neutral Sentiment: Recent comparisons with GRAIL and Vertex Pharmaceuticals provide valuation and operating-context analysis but do not identify a specific new catalyst for GILD. Contrasting GRAIL and Gilead Sciences Gilead Sciences versus Vertex Pharmaceuticals
• Negative Sentiment: Gilead’s upcoming third-quarter earnings report is expected to show a double-digit year-over-year EPS decline. That forecast is weighing on sentiment despite optimism about the company’s longer-term pipeline and product growth. Earnings Preview: What to Expect From Gilead Sciences’ Report

Gilead Sciences Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.